Neurotechnology Startup Funding 2025-2026

What are all the funding deals in the neurotechnology market from July 2025 to June 2026?

The table below lists every disclosed equity round raised by pure-play neurotechnology companies between July 2025 and June 2026. We count as “pure-play” neurotechnology companies those focused on products that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how neurotechnology fits inside the broader medical-device, BCI, and brain-health opportunity, we cover it in our Neurotechnology market report.

How active has fundraising been in the neurotechnology market?

As of June 2026, fundraising in the neurotechnology market has been active but lumpy. Over the past 12 months, companies raised 22 disclosed equity rounds and $1.56B combined, which works out to 1.83 deals per month.

That is enough activity to show that the neurotechnology market is investable, but not enough to suggest a broad, smooth funding cycle. May 2026 and early June 2026 had no qualifying disclosed deals in the dataset.

Capital flow was even more uneven than deal flow. The neurotechnology market averaged $130.20M raised per month, but the median month was only $64.23M, which shows how heavily the total depends on a few high-dollar windows.

November 2025 and March 2026 were the real funding peaks. Together, they produced 10 of the 22 deals and $828.70M, so nearly half of deal activity clustered in just two months.

If you want to go deeper on the companies behind this activity, see our market report covering neurotechnology funding.

How concentrated has fundraising been in the neurotechnology market?

As of June 2026, fundraising in the neurotechnology market has been highly concentrated. Over the past 12 months, the top 1 deal represented 16.13% of disclosed capital, the top 3 reached 43.65%, and the top 5 reached 59.33%.

The top 10 deals captured 85.96% of all disclosed capital. That means the headline total is mostly a story about a small set of large financings, not an evenly funded market.

The concentration is also visible below the top deal. Twelve rounds were larger than $50M, and six rounds were larger than $100M, so the neurotechnology market had repeated megarounds rather than one isolated outlier.

This matters because the $1.56B total can sound like broad market acceleration. A better reading is that investors funded a limited number of companies with unusually strong platform, clinical, or commercialization narratives.

How much of the neurotechnology funding signal is driven by outliers?

As of June 2026, the neurotechnology funding signal is strongly driven by outliers. Over the past 12 months, rounds above $50M made up 54.55% of all deals, while the entire sub-$50M universe added only $110.36M.

That below-$50M subtotal is just about 7.06% of total disclosed capital. In practical terms, small and mid-sized rounds exist in the neurotechnology market, but they do not explain the market’s dollar momentum.

The average round size was $71.02M, while the median was $54.50M. The gap is not extreme, but it still shows that large rounds are pulling the average upward.

The biggest distortion sits inside Seed. Merge Labs raised $252M at Seed, which makes the Seed category look far richer than ordinary early-stage neurotechnology fundraising really is.

Is the neurotechnology market broad with many targets, or narrow with few fundable companies?

As of June 2026, the neurotechnology market is narrow rather than broad. Over the past 12 months, the dataset contains 22 disclosed deals across only 21 unique companies.

Only Beacon Biosignals appears twice in the included company list, through its original Series B and later Series B extension. That means the market was not dominated by repeated raises from many companies.

The narrowness comes from the number of fundable companies that could support large checks. Twelve of the 22 rounds were above $50M, which suggests investors were selective but willing to fund aggressively when conviction was high.

The category spread also shows concentration. Brain Computer Interfaces captured 9 deals and $954.96M, while Clinical Neurosoftware had only 1 qualifying deal and $4.60M.

Is neurotechnology mostly an early-stage formation market or a late-stage scaling market?

As of June 2026, the neurotechnology market is split between early-stage formation and late-stage scaling. Over the past 12 months, Seed, Series A, and Series B rounds accounted for 14 deals and $653.16M, while Series C, Series D+, and Growth Equity rounds accounted for 6 deals and $802.50M.

By deal count, early-stage activity looks more common. Early-stage rounds represented 63.64% of all disclosed deals, which shows that investors are still forming and validating new neurotechnology companies.

By dollars, late-stage activity is larger. Late-stage rounds represented 51.36% of disclosed capital, which means the biggest checks went to companies closer to commercialization, pivotal trials, regulatory milestones, or broader launch readiness.

The Seed number should be read with one important caveat. Seed rounds totaled $330.16M, but Merge Labs alone contributed $252M, so ordinary Seed appetite is much smaller than the headline suggests.

For more context on how maturity differs by category, read our deeper analysis of the neurotechnology market.

Which categories attract the most investor attention in neurotechnology?

As of June 2026, Brain Computer Interfaces attracted the most investor attention in the neurotechnology market. Over the past 12 months, BCI companies raised 9 deals and $954.96M, representing 40.91% of deals and 61.12% of capital.

That gap between deal share and dollar share is important. BCI was not only the most active category; it also attracted larger checks than its deal count alone would predict.

Neuromodulation Devices ranked second with 5 deals and $322.10M. The category was funded roughly in line with its deal count, which makes it steadier but less capital-intensive than BCI.

Neuro Monitoring Tools produced 4 deals and $179.50M, while EEG Analytics Platforms produced 3 deals and $101.20M. Clinical Neurosoftware barely registered, with one AI-Stroke round representing only 0.29% of total capital.

Which categories attract disproportionately large checks in the neurotechnology market?

As of June 2026, Brain Computer Interfaces attracted disproportionately large checks in the neurotechnology market. Over the past 12 months, BCI held 61.12% of capital against 40.91% of deals, giving it a capital-share-to-deal-share ratio of 1.49.

That ratio shows that investors were not just funding more BCI companies. They were writing larger checks into the category because BCI offers platform optionality across medicine, computing, accessibility, and human-machine interaction.

Neuromodulation Devices sat closer to balance, with a ratio of 0.91. That suggests the category was fundable and clinically legible, but did not command the same strategic premium as BCI.

Neuro Monitoring Tools, EEG Analytics Platforms, and Clinical Neurosoftware all had ratios below 1.0. In the neurotechnology market, capital intensity clearly favored direct interface and stimulation technologies over lighter software or analytics layers.

Which geographies matter most for fundraising in the neurotechnology market?

As of June 2026, North America mattered most for fundraising in the neurotechnology market. Over the past 12 months, the region produced 14 deals and $1.27B, equal to 63.64% of deals and 81.10% of disclosed capital.

North America did not only lead by volume. Its average deal size was $90.50M and its median deal size was $70.50M, both far ahead of Europe’s median of $4.60M.

Europe ranked second by deal count, with 5 deals and $166.76M. Its funding profile was barbelled, because CoMind’s $102.5M round and ONWARD Medical’s $55M raise carried most of the region’s capital.

Asia-Pacific produced 3 deals and $128.60M. Temple, StairMed, and Mave Health made the region visible, but the neurotechnology market was not yet deep there during this 12-month window.

If you want to compare the regional opportunity more closely, see our full market report on neurotechnology.

Is the neurotechnology opportunity set broad or concentrated in one hub?

As of June 2026, the neurotechnology opportunity set is concentrated in one main hub. Over the past 12 months, North America captured 81.10% of disclosed capital and 63.64% of disclosed deals.

Europe and Asia-Pacific were visible, but both were secondary. Europe contributed 10.67% of disclosed capital, while Asia-Pacific contributed 8.23%.

The absence of Latin America, the Middle East, and Africa is also meaningful. No qualifying disclosed equity rounds from those regions appeared in the dataset.

This geographic pattern suggests the neurotechnology market still depends on ecosystems with specialized medtech investors, regulatory expertise, clinical translation capacity, and device-manufacturing infrastructure.

Is neurotechnology a market of small experiments or scaled financings?

As of June 2026, the neurotechnology market is a market of scaled financings, not just small experiments. Over the past 12 months, 12 of 22 disclosed rounds were $50M or larger.

The size distribution is top-heavy. Four deals were under $5M, four were between $5M and under $20M, two were between $20M and under $50M, and 12 were $50M or larger.

Rounds above $100M were also common. Six deals cleared that threshold, representing 27.27% of all disclosed deals in the neurotechnology market.

The median round size was $54.50M, which is already large for a category often discussed as frontier science. This confirms that visible neurotechnology financing is increasingly tied to clinical-stage, platform-scale, or commercialization-ready companies.

We cover the funding thresholds and company examples in more detail in our market report covering neurotechnology scale financings.

Who are the investors that appear the most in neurotechnology fundraising?

As of June 2026, repeat investors were rare in the neurotechnology market. Over the past 12 months, Khosla Ventures was the only clearly verifiable investor with more than one included deal in the strict dataset.

Khosla Ventures appeared in Synchron and Science Corporation, two BCI-related companies with large disclosed rounds. That makes Khosla the clearest multi-company investor signal in the dataset.

Nexus NeuroTech Ventures would have appeared more than once if Ampa had been included, but Ampa was excluded under the strict-period rule. Under the included dataset, Nexus appears only once.

This investor analysis has a limitation. Investor disclosure was incomplete or not comparable across several rounds, especially public or private placements, strategic financings, and some seed rounds.

The better conclusion is that the neurotechnology market has strong deal-level investor interest, but weak repeat-investor visibility. For more investor context, see our neurotechnology market deck.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.